[go: up one dir, main page]

NO20035675D0 - Krystallinske former av (R-(R*,R*))-2-(4-fluorfenyl)- <beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1) (Atorvastatin) - Google Patents

Krystallinske former av (R-(R*,R*))-2-(4-fluorfenyl)- <beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1) (Atorvastatin)

Info

Publication number
NO20035675D0
NO20035675D0 NO20035675A NO20035675A NO20035675D0 NO 20035675 D0 NO20035675 D0 NO 20035675D0 NO 20035675 A NO20035675 A NO 20035675A NO 20035675 A NO20035675 A NO 20035675A NO 20035675 D0 NO20035675 D0 NO 20035675D0
Authority
NO
Norway
Prior art keywords
atorvastatin
phenylamino
methylethyl
fluorophenyl
pyrrole
Prior art date
Application number
NO20035675A
Other languages
English (en)
Other versions
NO326170B1 (no
Inventor
Stephen Robert Byrn
David Andrew Coates
Karen Sue Gushurst
Ii Henry Grant Morrison
Aeri Park
Petinka Ivanova Vlahova
Joseph Francis Krzyzaniak
Jane Li
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23166039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20035675(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20035675D0 publication Critical patent/NO20035675D0/no
Publication of NO326170B1 publication Critical patent/NO326170B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20035675A 2001-06-29 2003-12-18 Krystallinske former av Atorvastatin NO326170B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30204901P 2001-06-29 2001-06-29
PCT/IB2002/001796 WO2003004470A1 (en) 2001-06-29 2002-05-21 Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)

Publications (2)

Publication Number Publication Date
NO20035675D0 true NO20035675D0 (no) 2003-12-18
NO326170B1 NO326170B1 (no) 2008-10-13

Family

ID=23166039

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035675A NO326170B1 (no) 2001-06-29 2003-12-18 Krystallinske former av Atorvastatin

Country Status (40)

Country Link
US (5) US6605729B1 (no)
EP (2) EP1423364B1 (no)
JP (2) JP3965155B2 (no)
KR (1) KR100609371B1 (no)
CN (2) CN101215253A (no)
AP (1) AP1571A (no)
AR (1) AR036118A1 (no)
AU (1) AU2002258092B2 (no)
BG (1) BG108393A (no)
BR (1) BR0210666A (no)
CA (1) CA2450111C (no)
CR (2) CR7170A (no)
CZ (1) CZ20033478A3 (no)
DO (1) DOP2002000413A (no)
EA (1) EA005317B1 (no)
EC (1) ECSP034928A (no)
EE (1) EE200300597A (no)
ES (1) ES2558565T3 (no)
GE (1) GEP20053546B (no)
HR (1) HRP20031039A2 (no)
HU (1) HUP0400381A2 (no)
IL (1) IL158790A0 (no)
MA (1) MA27044A1 (no)
MX (1) MXPA03010266A (no)
MY (1) MY122907A (no)
NO (1) NO326170B1 (no)
NZ (1) NZ529557A (no)
OA (1) OA12636A (no)
PA (1) PA8549501A1 (no)
PE (1) PE20030124A1 (no)
PL (1) PL367943A1 (no)
RS (1) RS100003A (no)
SK (1) SK16002003A3 (no)
SV (1) SV2003001144A (no)
TN (1) TNSN03147A1 (no)
TW (1) TWI319396B (no)
UA (1) UA74075C2 (no)
UY (1) UY27359A1 (no)
WO (1) WO2003004470A1 (no)
ZA (1) ZA200308731B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE69634054T2 (de) 1995-07-17 2005-12-08 Warner-Lambert Co. Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko) * 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
EP1423364B1 (en) * 2001-06-29 2015-11-04 Warner-Lambert Company LLC Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2003070702A1 (en) * 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
IL163594A0 (en) * 2002-02-19 2005-12-18 Teva Pharma Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
EP1562583A1 (en) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin calcium form vi or hydrates thereof
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP1711197A4 (en) * 2003-12-23 2008-11-05 Musc Found For Res Dev METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
SI1727795T1 (sl) 2004-03-17 2012-05-31 Ranbaxy Lab Ltd Postopek za pripravo atorvastatin kalcija v amorfni obliki
EP1745020A2 (en) 2004-05-05 2007-01-24 Pfizer Products Incorporated Salt forms of atorvastatin
MX2007000765A (es) * 2004-07-20 2007-03-28 Warner Lambert Co Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
EP1694685A1 (en) * 2004-09-28 2006-08-30 Teva Pharmaceutical Industries Ltd Process for preparing forms of atorvastatin calcium substantially free of impurities
KR20070067175A (ko) * 2004-10-28 2007-06-27 워너-램버트 캄파니 엘엘씨 무정형 아토르바스타틴 형성 방법
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2588216A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
EP1688850A1 (en) 2005-02-07 2006-08-09 Sony Ericsson Mobile Communications AB Generic parser for electronic devices
US8506646B2 (en) * 2005-04-29 2013-08-13 Warsaw Orthopedic, Inc. Multi-purpose medical implant devices
US8092464B2 (en) * 2005-04-30 2012-01-10 Warsaw Orthopedic, Inc. Syringe devices and methods useful for delivering osteogenic material
BRPI0520669A2 (pt) * 2005-11-21 2009-06-02 Teva Pharma dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
EP1923057A1 (en) * 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
DE602006014193D1 (de) 2005-11-21 2010-06-17 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium
MX2007014329A (es) * 2005-12-13 2008-03-19 Teva Pharma Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100878140B1 (ko) * 2007-01-29 2009-01-12 한미약품 주식회사 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
KR101012917B1 (ko) * 2007-03-02 2011-02-08 동아제약주식회사 피롤 헵탄산 화합물의 신규한 결정형
US20080227846A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
WO2008123953A1 (en) * 2007-04-02 2008-10-16 Merck & Co., Inc. Anti-hypercholesterolemic compound
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
CN102976996B (zh) * 2009-05-27 2015-08-19 峡江和美药业有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
US10450957B2 (en) 2017-01-23 2019-10-22 United Technologies Corporation Gas turbine engine with heat pipe system
WO2020013330A1 (ja) * 2018-07-13 2020-01-16 協和発酵バイオ株式会社 ユーコミン酸の非溶媒和物結晶及びその製造方法
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
SG45369A1 (en) 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE69634054T2 (de) 1995-07-17 2005-12-08 Warner-Lambert Co. Kristalline (R-(R*, R*))-2-(4-Fluorophenyl)-β, δ-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-1H-Pyrrol-1-Heptancarbonsäure Hemi Calcium Salz (Atorvastatin)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
AU3515497A (en) 1996-07-29 1998-02-20 Warner-Lambert Company Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
IN191236B (no) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
SI1535613T1 (sl) 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
ATE320415T1 (de) * 1999-12-17 2006-04-15 Pfizer Science & Tech Ltd Verfahren zur herstellung von kristallin atorvastin kalcium
IL149087A0 (en) * 1999-12-17 2002-11-10 Warner Lambert Res & Dev Ie A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
IL155890A0 (en) 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko) * 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (no) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
EP1423364B1 (en) * 2001-06-29 2015-11-04 Warner-Lambert Company LLC Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
MX2007014329A (es) * 2005-12-13 2008-03-19 Teva Pharma Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms

Also Published As

Publication number Publication date
TNSN03147A1 (en) 2005-12-23
DOP2002000413A (es) 2003-07-15
EP3009423A3 (en) 2016-12-28
JP2005501032A (ja) 2005-01-13
SV2003001144A (es) 2003-03-18
KR100609371B1 (ko) 2006-08-08
JP3965155B2 (ja) 2007-08-29
US20040054193A1 (en) 2004-03-18
AP2003002936A0 (en) 2003-12-31
MA27044A1 (fr) 2004-12-20
PE20030124A1 (es) 2003-02-12
AP1571A (en) 2006-02-10
AR036118A1 (es) 2004-08-11
US6605729B1 (en) 2003-08-12
EE200300597A (et) 2004-02-16
BG108393A (bg) 2004-12-30
RS100003A (sr) 2007-02-05
HRP20031039A2 (en) 2005-10-31
US20060241169A1 (en) 2006-10-26
US20080287521A1 (en) 2008-11-20
ECSP034928A (es) 2004-02-26
TWI319396B (en) 2010-01-11
HUP0400381A2 (hu) 2004-09-28
CN101215253A (zh) 2008-07-09
UY27359A1 (es) 2003-04-30
ES2558565T3 (es) 2016-02-05
CN1524073A (zh) 2004-08-25
PL367943A1 (en) 2005-03-07
NZ529557A (en) 2005-05-27
PA8549501A1 (es) 2003-09-05
US7144915B2 (en) 2006-12-05
CR9741A (es) 2008-10-31
AU2002258092B2 (en) 2007-05-17
OA12636A (en) 2006-06-15
KR20040014583A (ko) 2004-02-14
GEP20053546B (en) 2005-06-10
BR0210666A (pt) 2004-10-05
US20080214651A1 (en) 2008-09-04
JP2007182460A (ja) 2007-07-19
EP3009423A2 (en) 2016-04-20
MXPA03010266A (es) 2004-03-10
IL158790A0 (en) 2004-05-12
SK16002003A3 (sk) 2004-12-01
EA200301243A1 (ru) 2004-06-24
CZ20033478A3 (cs) 2004-10-13
WO2003004470A1 (en) 2003-01-16
EA005317B1 (ru) 2004-12-30
CA2450111C (en) 2006-02-07
NO326170B1 (no) 2008-10-13
CR7170A (es) 2004-02-23
EP1423364A1 (en) 2004-06-02
AU2002258092C1 (en) 2003-01-21
CA2450111A1 (en) 2003-01-16
MY122907A (en) 2006-05-31
ZA200308731B (en) 2004-11-10
UA74075C2 (en) 2005-10-17
EP1423364B1 (en) 2015-11-04

Similar Documents

Publication Publication Date Title
NO20035675D0 (no) Krystallinske former av (R-(R*,R*))-2-(4-fluorfenyl)- &lt;beta&gt;,&lt;delta&gt;-dihydroksy-5-(1-metyletyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1) (Atorvastatin)
IL128864A0 (en) Crystalline (R-(R*R*)-2-(4-fluorophenyl)-beta- delta-dihydroxy-5- (1-methylethyl)-3--phenyl-4-(phenylamino)carbonyl)-IH-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
EE9700369A (et) Protsess amorfse [R-(R*,R*)]-2-(4-fluorofenüül)-ß,š-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)- karbonüül]-1H-pürrool-1-heptaanhappe kaltsiumsoola (2:1) tootmiseks
SI1499297T1 (sl) Farmacevtska oblika, ki vsebuje atorvastatin kalcij
CA2435954A1 (en) Preparation of non-crystalline atorvastatin calcium
PL370061A1 (en) Crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1)
MX9708857A (es) Forma iii cristalina de la sal de calcio hemi del acido (r-(r*,r*)-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metil -etil-)-3-fenil-4-((fenilamino)carbonil)-1h-pirrole-1-heptan oico(atorvastatina).
MXPA04000889A (es) Formas cristalinas vi y vii de atorvastatina calcica.
HUP0402590A3 (en) Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
WO2005105738A3 (en) Salt forms of atorvastatin
AU2003297594A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
NO975499D0 (no) Form III krystallinsk (R-(R*,R*)-2(4-fluorfenyl)-&lt;beta&gt;-&lt;delta&gt;-dihydroksy-(1-metyl-etyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-hemi-kalsiumsalt
IL173651A0 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
SI0848704T1 (en) Form iii crystalline (r-(r*,r*))-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
IS7019A (is) Kristallaform af &#39;R-(R*,R*)!-2-(4-flúorfenýl)-beta, delta-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-&#39;fenýlamínó)karbónýl!-1H-pýrról-1-heptansýru kalsíum salt (2:1) (atorvastatín)
AU2001234058A1 (en) Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin)
PL349307A1 (en) Novel crystalline form of semi-calcium [r-(r ,r)]-2-(4-fluorophenyl)-beta, dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl)-1h-pyrrole-1-heptanic salt (athorovastatin), method of obtaining same, pharmacological composition containing such salt and medical application thereof
AU2003278597A1 (en) (r-(r*,r*))-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-((1-methylethyl) -3-phenyl-4-((phenylamino) carbonyl)- 1h-pyrrole-1-heptanoic acid iron salt
HK1056556A (en) HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β, δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE